by Jordana Choucair | Jan 25, 2022 | Life Sciences
The FDA restricted the use of COVID-19 antibody treatments that don’t appear effective against the Omicron variant. The agency saying the decision will be in place while the strain is dominant. Some health systems stopped using the treatments weeks ago, although...
by Jordana Choucair | Jan 25, 2022 | Life Sciences
Johnson & Johnson said it expects its COVID-19 vaccine to bring in up to $3.5 billion this year, up from $2.39 billion in 2021. Still, contributions from its COVID-19 vaccine are a small percentage of the company’s total revenue because it sells its vaccine at a...
by Jordana Choucair | Jan 25, 2022 | Life Sciences
Pfizer Inc. and BioNTech SE said they are testing a version of their COVID-19 vaccine that targets the Omicron variant. Pfizer said results are expected in the first half of the year so that an Omicron-specific vaccine is available “should it be needed.”...
by Jordana Choucair | Jan 24, 2022 | Life Sciences
The FDA is weighing whether to limit the authorization of monoclonal antibody treatments from Eli Lilly & Co. and Regeneron Pharmaceuticals Inc., which haven’t proved effective against the Omicron variant. According to a person familiar with the process,...
by Jordana Choucair | Jan 24, 2022 | Life Sciences
Pfizer Inc. CEO Albert Bourla said the drugmaker hopes to offer an annual COVID-19 vaccine because it “will not be a good scenario” if people have to get more frequent booster shots. He said Pfizer aims to develop a vaccine that “covers omicron and...
by Jordana Choucair | Jan 20, 2022 | Life Sciences
A new analysis by the Congressional Budget Office found that savings from generics have driven average prescription prices down in Medicare and Medicaid. Between 2018 and 2019, the average price for a generic prescription fell in both program while the use jumped from...
Recent Comments